This was notable, as GATA-3 expression identifies PTCL and CTCL that are clinically, genetically, and transcriptionally distinct, owing to their dependence upon a GATA-3-driven transcriptional program and a genetic landscape associated with increased biomass production suitable to meet the demands of these highly proliferative T-cell lymphomas [2, 5, 11, 50, 51]. The gene discussed is GATA3; the disease is T-cell non-Hodgkin lymphoma.